---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Prevalence"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Prevalence. Topics: United States: 12-month prevalence of TRD among adults with medication-treated MDD; United States: TRD population cited in the ICER draft scope; United States: past-year major depressive episode among adults, NSDUH 2025; United States: 12-month and lifetime prevalence of DSM-5 MDD, NESARC-III; 10 further topics. 14 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Treatment-resistant depression

<a id="topic-2.2.1.2.2-1"></a>

### United States: 12-month prevalence of TRD among adults with medication-treated MDD

> “Prevalence and health care burden of TRD were estimated by synthetizing inputs across 4 similarly designed claims studies in adults covered by Medicare, Medicaid, commercial plans, and the US Veterans Health Administration (VHA).”
> “The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.”

Source: [Zhdanava et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33989464/)

<a id="topic-2.2.1.2.2-2"></a>

### United States: TRD population cited in the ICER draft scope

> “Many Americans with MDD do not receive treatment at all, but among those who do, an estimated 2.8 million experience treatment-resistant depression (TRD).”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-2.2.1.2.2-3"></a>

### United States: past-year major depressive episode among adults, NSDUH 2025

> “Among adults aged 18 or older, the percentage who had a past year MDE decreased from 8.5 percent (or 21.6 million people) in 2021 to 7.4 percent (or 19.7 million people) in 2025”
> “The percentage of adults aged 18 or older who had a past year MDE with severe impairment also decreased from 5.9 percent (or 14.9 million people) in 2021 to 5.2 percent (or 13.8 million people) in 2025”
> “Of these adults with a past year MDE, 65.9 percent (or 13.0 million people) received any of the types of mental health treatment in the past year that were described previously”
> “Among adults who had an MDE in the past year, 51.7 percent (or 10.2 million people) took prescription medication to help with their mental health”

Source: [SAMHSA (2026)](https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm)

<a id="topic-2.2.1.2.2-4"></a>

### United States: 12-month and lifetime prevalence of DSM-5 MDD, NESARC-III

> “Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively.”

Source: [Hasin et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875313/)

<a id="topic-2.2.1.2.2-5"></a>

### United States: cumulative remission across four treatment steps, Sequenced Treatment Alternatives to Relieve Depression trial

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.1.2.2-6"></a>

### United States: Sequenced Treatment Alternatives to Relieve Depression trial participants without remission after two treatment trials

> “In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a third of patients did not achieve remission or adequate response after two treatment trials, fulfilling requirements for treatment resistant depression (TRD).”

Source: [DiBernardo et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206859/)

<a id="topic-2.2.1.2.2-7"></a>

### United States: estimate based on the Sequenced Treatment Alternatives to Relieve Depression trial under FDA and EMA criteria, and range across settings

> “TRD is often stated to affect approximately 30% of persons receiving antidepressant treatment in research settings, while its prevalence in real world practice is estimated to range between 6 and 55%”
> “The FDA and EMA definitions of TRD would align with failure to level 1 and 2 treatments in the STAR*D trial.”
> “In summary, while it is often stated that TRD is affecting approximately 30% of persons receiving antidepressant treatment, a more stringent and multidimensional definition of this condition emphasizing symptomatic remission increases this estimate to about 55%.”

Source: [McIntyre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/)

<a id="topic-2.2.1.2.2-8"></a>

### United States commercial claims: share of treated depression meeting a data-driven TRD rule

> “The rule transported well and states that a subject with ≥1 antipsychotic or ≥3 antidepressants in the last year has TRD. Applying this rule, 15.8% of subjects treated for depression had TRD.”

Source: [Cepeda et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5873404/)

<a id="topic-2.2.1.2.2-9"></a>

### United Kingdom primary care: patients on repeat antidepressant prescriptions

> “Those who scored ≥14 on the BDI-II and had taken antidepressants for at least 6 weeks at an adequate dose were defined as treatment resistant.”
> “Fifty-five per cent (95% CI = 53% to 58%) (n = 1177) met the study’s definition of TRD, of whom 67% had taken their antidepressants for more than 12 months.”

Source: [Thomas et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3839394/)

<a id="topic-2.2.1.2.2-10"></a>

### Canada primary care: consecutive patients with MDD

> “Using failure to respond to at least 2 antidepressants (ADs) from different classes as the definition of TRD, the overall prevalence was 21.7%.”
> “The prevalence across provinces varied (P < 0.001), with British Columbia having the highest rate (28.7%) and Alberta the lowest rate (12.8%).”

Source: [Rizvi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086317/)

<a id="topic-2.2.1.2.2-11"></a>

### United Kingdom primary care records: UK Biobank and EXCEED

> “Among individuals with MDD with at least one record of antidepressant prescription, the prevalence of TRD was 13.49% (n = 159) and 13.2% (n = 2430) in EXCEED and UKB, respectively”

Source: [Fabbri et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8505242/)

<a id="topic-2.2.1.2.2-12"></a>

### Scotland and UK Biobank health records: proportion by definition

> “The reference TRD definition included 10% of depression cases in the routine data collection, but substantially fewer cases (4%) in consented cohorts.”

Source: [Iveson et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13245096/)

<a id="topic-2.2.1.2.2-13"></a>

### Sweden, national registers: antidepressant initiators classified with TRD

> “Patients with at least two additional treatment trials during the same depressive episode were classified as having TRD.”
> “In total 15,013 patients (13%) were classified with TRD.”

Source: [Reutfors et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29966932/)

<a id="topic-2.2.1.2.2-14"></a>

### France, national claims sample: annual prevalence

> “Annual incidence and prevalence of TRD were estimated at 5.8 and 25.8 per 10 000 patients, respectively and at 7.8 and 37.6 per 10 000 patients, respectively in the sensitivity analysis.”

Source: [Bosco-Lévy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767421/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
